Antiarrhythmic effects of bisaramil in canine models of ventricular arrhythmia.
The antiarrhythmic effects of bisaramil were examined in canine models of digitalis-, adrenaline- and two-stage coronary ligation- induced arrhythmia. Bisaramil (0.3-1.5 mg/kg i.v.) suppressed all the arrhythmias. The antiarrhythmic plasma concentration (IC50) for arrhythmias induced by digitalis, adrenaline, and 24 h two-stage coronary ligation were 0.11, 0.81, and 0.75 micrograms/ml, respectively. Bisaramil is a potent class I agent, judging from its low antiarrhythmic plasma concentrations. Oral bisaramil (10 mg/kg) also suppressed 24-h coronary ligation-induced arrhythmia. These results indicate that bisaramil may be a useful drug for the treatment of various clinical ventricular arrhythmias.
Haruno
A
A
Department of Pharmacology, Yamanashi Medical College, Japan.
Hashimoto
K
K
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000097:blood / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*; D001643:Bridged Bicyclo Compounds / Q000097:blood / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002722:Chlorobenzenes; D003331:Coronary Vessels / Q000502:physiology; D004071:Digitalis Glycosides; D004285:Dogs; D004562:Electrocardiography / Q000187:drug effects; D004837:Epinephrine; D005260:Female; D006352:Heart Ventricles / Q000503:physiopathology; D066298:In Vitro Techniques; D008297:Male
D000889:Anti-Arrhythmia Agents; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002722:Chlorobenzenes; D004071:Digitalis Glycosides; C045644:bisaramil; D004837:Epinephrine